 BRISBANE, Calif., March 03, 2022 GLOBE NEWSWIRE -- Annexon, Inc. Annexon Nasdaq: ANNX, a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that the company will present preclinical data highlighting its approach of inhibiting C1q to address a number of complement-mediated diseases. The data are being presented in oral and poster sessions at the American Academy of Neurology AAN Annual meeting, being held in Seattle from April 2-7, 2022, and virtually from April 24-26, 2022. 